XML 59 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Fair value of financial instruments and marketable securities - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
May 31, 2019
Jan. 31, 2019
Dec. 31, 2018
Aug. 23, 2018
Aug. 31, 2015
Financial assets and liabilities measured at fair value on recurring basis                
Realized gain (loss)   $ 0            
Fair value of shares (in dollars per share)         $ 30.20      
Estimated fair value of deferred consideration payable $ 18,800,000 18,800,000       $ 18,300,000    
Deferred consideration payable 19,400,000 19,400,000       19,400,000    
Unrealized Gain (Loss) on Investments   129,000 $ 0          
Investment In MRI 4,100,000 4,100,000            
3.00% Convertible senior notes due 2022 | Convertible debt                
Financial assets and liabilities measured at fair value on recurring basis                
Principal 150,000,000 150,000,000       150,000,000   $ 150,000,000.0
Interest rate ( as a percent )               3.00%
Fair value of convertible notes $ 166,200,000 $ 166,200,000       146,600,000    
Agilis                
Financial assets and liabilities measured at fair value on recurring basis                
Development milestone payments which the entity is obligated to pay             $ 40,000,000.0  
Agilis | Minimum                
Financial assets and liabilities measured at fair value on recurring basis                
Milestone, potential achievements, product sales 2.00% 2.00%            
Agilis | Maximum                
Financial assets and liabilities measured at fair value on recurring basis                
Milestone, potential achievements, product sales 6.00% 6.00%            
Development milestone payments which the entity is obligated to pay $ 60,000,000.0 $ 60,000,000.0            
Milestone, potential achievements, priority review voucher amount   535,000,000.0            
Milestone, potential achievements, net sales amount 150,000,000.0 150,000,000.0            
Non-collaborative Arrangement Transactions | Agilis                
Financial assets and liabilities measured at fair value on recurring basis                
Development milestone payments which the entity is obligated to pay 40,000,000.0 40,000,000.0            
Recurring basis | Total                
Financial assets and liabilities measured at fair value on recurring basis                
Estimated fair value of deferred consideration payable 38,200,000 38,200,000       $ 37,700,000    
Common stock                
Financial assets and liabilities measured at fair value on recurring basis                
Investment Owned, Balance, Shares       $ 4,000,000.0        
Fair value of shares (in dollars per share)       $ 3.10        
Unrealized Gain (Loss) on Investments $ 100,000 $ 100,000